21 Oct ACG 2022 Annual Scientific Meeting, Charlotte, North Carolina

ASX:RHT

Resonance Health

Clinician Update – October 2023

Launch of HepaFatSmart™ HepaFatSmart™, formerly known as HepaFat-AI, has been redeveloped with a statistical performance now comparable to HepaFatScan®. There has been significant improvement to error reporting with clearer messaging, and improved error detection to minimise undesired impacts on analysis result and to reduce failure rate due to previously strict input quality control rules. Each …

Clinician Update – October 2023 Read More »

FerriScan® is now available on 3T MRI scanners!

Resonance Health Ltd announces the development of its newest AI medical device, LiverSmart, which is now undergoing final quality and verification checks prior to its submission to the United States Food & Drug Administration (FDA) for regulatory clearance.

LiverSmart combines two existing regulatory-cleared Resonance Health products, FerriSmart® and HepaFat-AI®, into a single multi-parametric MRI session, avoiding the need for multiple MRI appointments, and delivering a more complete and comprehensive assessment of a person’s liver.